# Syntekabio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/syntekabio

- Industry: Biotechnology
- Headquarters: Daejeon, South Korea
- Website: www.syntekabio.com
- Total disclosed funding: $33M
- Latest round: Series C (Jul 1, 2019)
- Investors on record: 13

## About

Based in South Korea, Syntekabio, Inc. specializes in AI-driven drug discovery, providing innovative platforms to enhance and expedite the drug development process for pharmaceutical companies and research institutions globally.Founded in 2009 and headquartered in Daejeon, South Korea, Syntekabio, Inc. focuses on AI-based solutions for drug development. The company has undergone significant growth, having raised KRW 19.2 billion in an IPO on December 17, 2019, and has completed a total of four deals. Jongsun Jung is the CEO, steering the company towards advancements in drug discovery.Syntekabio is a leader in AI-driven drug discovery, offering a range of innovative products and services aimed at streamlining the drug development process. Their core offerings include the DeepMatcher AI Drug Platform, which enables continuous and automated production of drug candidates through a factory-like model of drug discovery. This platform provides significant advantages in generating drug candidates for over 100 disease targets, facilitating the rapid validation of candidates for Investigational New Drug (IND) status. The company also specializes in tailored solutions such as the Sm-ARS for small molecule drugs, NEO-ARS for neoantigen prediction in cancer therapies, and Ab-ARS for antibody drug candidates. Syntekabio serves a global client base that includes pharmaceutical companies, academic institutions, and research organizations across markets such as North America, Europe, and Asia, focusing on addressing critical therapeutic areas and accelerating the drug development lifecycle.For the most recent year 2024, Syntekabio reported a revenue of KRW 88,692.2 mn, with an EBITDA amounting to KRW -9,104,106.4. The company's revenue model is primarily structured around a Software as a Service (SaaS) approach, allowing clients to access their advanced drug discovery platforms and solutions through various service tiers tailored to meet specific research needs.Syntekabio plans to utilize the funding raised during its IPO to accelerate the development of its drug discovery pipeline. The company is likely focusing on upcoming products designed to enhance its existing platforms, and is targeting expansion into new geographic markets, although specific regions and timelines for this expansion have not been disclosed.

## Funding rounds

- Series C, Jul 1, 2019, $17M — Altos Ventures, Meritz Securities, CJ Investment, Saehan Venture Capital, KB Securities, Must Ventures, Yuhan Corporation, Korea Asset Investment Securities, Asam Asset Management
- Series B, May 8, 2018, $11M — Altos Ventures, Korea Development Bank, Smilegate Investment, Korea Fixed-Income Investment Advisory, Yozma Group Korea
- Series A, Jun 24, 2016, $5.1M — Altos Ventures

## Investors

- Altos Ventures (https://capitalatlas.ai/funds/altos-ventures) — Series A, Series B, Series C
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series B
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series B
- Korea Fixed-Income Investment Advisory — Series B
- Yozma Group Korea (https://capitalatlas.ai/funds/yozma-group-korea) — Series B
- Meritz Securities — Series C
- CJ Investment (https://capitalatlas.ai/funds/cj-investment) — Series C
- Saehan Venture Capital (https://capitalatlas.ai/funds/saehan-venture-capital) — Series C
- KB Securities (https://capitalatlas.ai/funds/kb-securities) — Series C
- Must Ventures (https://capitalatlas.ai/funds/must-ventures) — Series C
- Yuhan Corporation — Series C
- Korea Asset Investment Securities (https://capitalatlas.ai/funds/korea-asset-investment-securities) — Series C
- Asam Asset Management — Series C